2025 Europe Allergy Immunotherapy Revenue Opportunities Report
Description
The 2025 Europe Allergy Immunotherapy Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Allergy Immunotherapy market in Europe are ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, and HAL Allergy B.V. ALK-Abelló, based in Denmark, is a market leader with a strong focus on sublingual immunotherapy (SLIT) tablets and subcutaneous immunotherapy (SCIT), holding a significant share of the European market through its advanced allergy vaccines and tablets approved by EMA. Stallergenes Greer, headquartered in the UK, specializes in personalized allergy immunotherapy and strengthened its European presence by acquiring Allergy Therapeutics, which itself focuses on next-generation injectable immunotherapy and has a robust UK base. HAL Allergy, based in the Netherlands, is also a key player, offering biologic allergy treatments and innovative formulations targeting European allergies.
Together, these companies dominate about one-third of the global allergy immunotherapy market and significantly influence the European market, which is valued at over USD 1.2 billion as of 2023 and projected to grow steadily with a CAGR around 10% through 2030. Their core focus includes expanding the range of allergenic extracts, enhancing product standardization, and developing new delivery methods like SLIT tablets and drops to improve patient adherence and outcomes. This competitive environment is reinforced by strict EMA regulations and ongoing investments in clinical trials to ensure safety and efficacy of treatments for allergic rhinitis, asthma, and other allergies prevalent across Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Allergy Immunotherapy market in Europe are ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, and HAL Allergy B.V. ALK-Abelló, based in Denmark, is a market leader with a strong focus on sublingual immunotherapy (SLIT) tablets and subcutaneous immunotherapy (SCIT), holding a significant share of the European market through its advanced allergy vaccines and tablets approved by EMA. Stallergenes Greer, headquartered in the UK, specializes in personalized allergy immunotherapy and strengthened its European presence by acquiring Allergy Therapeutics, which itself focuses on next-generation injectable immunotherapy and has a robust UK base. HAL Allergy, based in the Netherlands, is also a key player, offering biologic allergy treatments and innovative formulations targeting European allergies.
Together, these companies dominate about one-third of the global allergy immunotherapy market and significantly influence the European market, which is valued at over USD 1.2 billion as of 2023 and projected to grow steadily with a CAGR around 10% through 2030. Their core focus includes expanding the range of allergenic extracts, enhancing product standardization, and developing new delivery methods like SLIT tablets and drops to improve patient adherence and outcomes. This competitive environment is reinforced by strict EMA regulations and ongoing investments in clinical trials to ensure safety and efficacy of treatments for allergic rhinitis, asthma, and other allergies prevalent across Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
